Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.46 |
| ▸ | GABRP | O00591 | 6/20 | 0.46 |
| ▸ | GABRD | O14764 | 6/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.46 |
| ▸ | GABRE | P78334 | 6/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019601 | 0.89 | CYP1A2 (0.59) | POLBCYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL23538019 | 0.88 | POLB (0.45) | POLBCYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL27635499 | 0.88 | SIRT6 (0.59) | POLBCYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL10329867 | 0.86 | MAPK1 (0.47) | POLBCYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL1644521 | 0.81 | POLB (0.70) | POLBCYP1A2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL991588 | 0.81 | MAPT (0.56) | CYP1A2LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL16935098 | 0.81 | MAPT (0.47) | POLBCYP1A2LMNAMAPTALDH1A1 | |
| SCHEMBL1644378 | 0.81 | CYP1A2 (0.52) | POLBCYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL18399949 | 0.81 | MAPT (0.41) | POLBGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15687895 | 0.81 | ALDH1A1 (0.49) | POLBCYP1A2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360779-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360781-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360780-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3009424-B1 | BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231424-A1 | PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE COMPONENT | Astellas Pharma Inc. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231426-A1 | PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETROCYCLIC AMIDE COMPOUNDS AS ACTIVE INGREDIENT | Astellas Pharma Inc. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231425-A1 | PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE COMPONENT | Astellas Pharma Inc. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-9687494-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9687494-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| EP-2456774-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011044181-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360779-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | ACAD9, NDUFAF1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | POLB 720/4885CYP1A2 1430/4885GABRA1 1924/4885 |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | POLB 2321/4885CYP1A2 613/4885GABRA1 2009/4885 |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | POLB 663/4885CYP1A2 243/4885GABRA1 2446/4885 |
| US-20170360780-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | ACAD9, UQCRC1, UQCRC2 | POLB 820/4885CYP1A2 1060/4885GABRA1 2517/4885 |
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | POLB 695/4885CYP1A2 305/4885GABRA1 2387/4885 |
| US-20170360781-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT | AK2, PRKAA1, ACAD9 | POLB 948/4885CYP1A2 1019/4885GABRA1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.